Literature DB >> 3095332

Quantitative evaluation of DNA binding data for risk estimation and for classification of direct and indirect carcinogens.

W K Lutz.   

Abstract

Investigation of covalent DNA binding in vivo provided evidence for whether a test substance can be activated to metabolites able to reach and react with DNA in an intact organism. For a comparison of DNA binding potencies of various compounds tested under different conditions, a normalization of the DNA lesion with respect to the dose is useful. A covalent binding index, CBI = (mumol chemical bound per mol DNA nucleotide)/(mmol chemical administered per kg body weight) can be determined for each compound. Whether covalent DNA binding results in tumor formation is dependent upon additional factors specific to the cell type. Thus far, all compounds which bind covalently to liver DNA in vivo have also proven to be carcinogenic in a long-term study, although the liver was not necessarily the target organ for tumor growth. With appropriate techniques, DNA binding can be determined in a dose range which may be many orders of magnitude below the dose levels required for significant tumor induction in a long-term bioassay. Rat liver DNA binding was proportional to the dose of aflatoxin B1 after oral administration of a dose between 100 micrograms/kg and 1 ng/kg. The lowest dose was in the range of general human daily exposures. Demonstration of a lack of liver DNA binding (CBI less than 0.1) in vivo for a carcinogenic, nonmutagenic compound is a strong indication for an indirect mechanism of carcinogenic action. Carcinogens of this class do not directly produce a change in gene structure or function but disturb a critical biochemical control mechanism, such as protection from oxygen radicals, control of cell division, etc. Ultimately, genetic changes are produced indirectly or accumulate from endogenous genotoxic agents. The question of why compounds which act via indirect mechanisms are more likely to exhibit a nonlinear range in the dose-response curve as opposed to the directly genotoxic agents or processes is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3095332     DOI: 10.1007/bf00404387

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  Disposition and metabolism of aniline in Fischer 344 rats and C57BL/6 X C3H F1 mice.

Authors:  D J McCarthy; W R Waud; R F Struck; D L Hill
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

2.  Saccharin does not bind to DNA of liver or bladder in the rat.

Authors:  W K Lutz; C Schlatter
Journal:  Chem Biol Interact       Date:  1977-11       Impact factor: 5.192

3.  In vivo binding of the flame retardants tris(2,3-dibromopropyl) phosphate and tris(1,3-dichloro-2-propyl) phosphate to macromolecules of mouse liver, kidney and muscle.

Authors:  N M Morales; H B Matthews
Journal:  Bull Environ Contam Toxicol       Date:  1980-07       Impact factor: 2.151

Review 4.  DNA adducts in experimental cancer research.

Authors:  K Hemminki; A Försti; R Mustonen; K Savela
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

5.  Investigation of the potential for binding of Di(2-ethylhexyl) phthalate (DEHP) and Di(2-ethylhexyl) adipate (DEHA) to liver DNA in vivo.

Authors:  A von Däniken; W K Lutz; R Jäckh; C Schlatter
Journal:  Toxicol Appl Pharmacol       Date:  1984-05       Impact factor: 4.219

6.  The relevance of covalent binding to mouse liver DNA to the carcinogenic action of hexachlorocyclohexane isomers.

Authors:  P Sagelsdorff; W K Lutz; C Schlatter
Journal:  Carcinogenesis       Date:  1983-10       Impact factor: 4.944

7.  32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice.

Authors:  K Randerath; R E Haglund; D H Phillips; M V Reddy
Journal:  Carcinogenesis       Date:  1984-12       Impact factor: 4.944

8.  Lack of covalent binding to rat liver DNA of the hypolipidemic drugs clofibrate and fenofibrate.

Authors:  A von Däniken; W K Lutz; C Schlatter
Journal:  Toxicol Lett       Date:  1981-02       Impact factor: 4.372

9.  Alkylation of DNA in rat tissues following administration of streptozotocin.

Authors:  R A Bennett; A E Pegg
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

10.  Postlabeling methods for carcinogen-DNA adduct analysis.

Authors:  K Randerath; E Randerath; H P Agrawal; R C Gupta; M E Schurdak; M V Reddy
Journal:  Environ Health Perspect       Date:  1985-10       Impact factor: 9.031

View more
  14 in total

1.  DNA binding and mutagenicity of lindane and its metabolites.

Authors:  U V Gopalaswamy; C K Nair
Journal:  Bull Environ Contam Toxicol       Date:  1992-08       Impact factor: 2.151

2.  Trenbolone growth promotant: covalent DNA binding in rat liver and in Salmonella typhimurium, and mutagenicity in the Ames test.

Authors:  W K Lutz; R Deuber; M Caviezel; P Sagelsdorff; U Friederich; C Schlatter
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

Review 3.  Evidence-Based Challenges to the Continued Recommendation and Use of Peroxidatively-Susceptible Polyunsaturated Fatty Acid-Rich Culinary Oils for High-Temperature Frying Practises: Experimental Revelations Focused on Toxic Aldehydic Lipid Oxidation Products.

Authors:  Martin Grootveld
Journal:  Front Nutr       Date:  2022-01-05

Review 4.  Experimental toxicology of formaldehyde.

Authors:  H M Bolt
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

5.  Complete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold.

Authors:  Natalie M Johnson; Patricia A Egner; Victoria K Baxter; Michael B Sporn; Ryan S Wible; Thomas R Sutter; John D Groopman; Thomas W Kensler; Bill D Roebuck
Journal:  Cancer Prev Res (Phila)       Date:  2014-03-24

6.  Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites.

Authors:  C E Frantz; H Chen; D A Eastmond
Journal:  Environ Health Perspect       Date:  1996-12       Impact factor: 9.031

Review 7.  Biochemical and molecular epidemiology of human cancer: indicators of carcinogen exposure, DNA damage, and genetic predisposition.

Authors:  C C Harris; A Weston; J C Willey; G E Trivers; D L Mann
Journal:  Environ Health Perspect       Date:  1987-11       Impact factor: 9.031

Review 8.  The mechanism of benzene-induced leukemia: a hypothesis and speculations on the causes of leukemia.

Authors:  M T Smith
Journal:  Environ Health Perspect       Date:  1996-12       Impact factor: 9.031

9.  Benzene adducts with rat nucleic acids and proteins: dose-response relationship after treatment in vivo.

Authors:  M Mazzullo; S Bartoli; B Bonora; A Colacci; S Grilli; G Lattanzi; A Niero; M P Turina; S Parodi
Journal:  Environ Health Perspect       Date:  1989-07       Impact factor: 9.031

Review 10.  Molecular epidemiologic research on the effects of environmental pollutants on the fetus.

Authors:  F P Perera; W Jedrychowski; V Rauh; R M Whyatt
Journal:  Environ Health Perspect       Date:  1999-06       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.